Short answer
Allogene Therapeutics, Inc. (ALLO) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026, announced alongside Allogene’s corporate update.
Allogene Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, announced alongside Allogene’s corporate update
- Financial details and operating developments contained in Exhibit 99.1 press release
- Investor focus: cash runway, clinical milestones and pipeline updates in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- ALPHA3 interim data: MRD negativity 58.3% with cema-cel vs 16.7% observation, a 41.6% absolute difference
- FDA RMAT and Fast Track designations strengthen cema-cel’s regulatory pathway in high-risk 1L LBCL
- Trial execution accelerating: over 80 sites activated, approximately 100 expected by year-end, enrollment completion targeted by year-end 2027
- Cash, cash equivalents and investments $423.6M, supporting projected runway into 2029
- Q2 net loss $42.7M, or $0.13 per share, with 2026 operating expense guidance approximately $165M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Allogene Therapeutics, Inc. 8-K filings
Get the next ALLO 8-K as it lands
Follow ALLO for push alerts, or ask the research agent what this filing means.